Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution;...
Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution;...
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile...
Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid ® -ineligible patients, representing a significant population...
Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property...
SAN DIEGO , Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services...
DOVER, Del. , Oct. 22, 2025 /PRNewswire/ -- Expert Systems Inc. , a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...
Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...